MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Opicapone’s Effects on Progression Scales in Relation to the 9-Symptom Wearing-off Questionnaire: the OPTIPARK Study

    D. Martins, A. Lees, H. Reichmann, J-F. Rocha (Coronado, Portugal)

    Objective: This study aims to evaluate changes in Parkinson’s disease (PD) progression scales in patients with PD and motor fluctuations (MF) treated with once-daily opicapone…
  • 2023 International Congress

    Long-term dementia prevalence in Parkinson disease: Glass half-full?

    J. Gallagher, J. Fedler, C. Gochanour, R. Dobkin, D. Aarsland, R. Alcalay, M. Barrett, C. Caspell-Garcia, R. Cho, L. Chahine, A. Chen-Plotkin, C. Coffey, N. Dahodwala, J. Eberling, A. Espay, J. Leverenz, I. Litvan, E. Mamikonyan, J. Morley, I. Richard, L. Rosenthal, A. Siderowf, T. Simuni, M. York, A. Willis, S. Xie, D. Weintraub (Philadelphia, USA)

    Objective: To determine long-term, cumulative dementia prevalence rates in Parkinson disease (PD) using data from two large, ongoing, prospective observational studies. Background: Dementia is reported to occur in…
  • 2023 International Congress

    Brain MRI volumetry analysis for patients with Parkinson’s disease suffering from REM sleep behavior disorder: a pilot study

    T. Vanagas, G. Paulekiene, A. Radziunas, R. Balnyte, E. Pajediene, E. Paulekas (Kaunas, Lithuania)

    Objective: To detect patients with Parkinson's disease that have REM sleep behavior disorder (RBD) and perform brain MRI volumetry analysis. Background: Parkinson’s disease is classically…
  • 2023 International Congress

    Frequency of Parkinson disease following COVID-19 infection: a two-year retrospective cohort study

    A. Wang, J. Perez, S. Gunzler (Cleveland, USA)

    Objective: We aimed to utilize a large healthcare research network to determine the risk of developing Parkinson disease following COVID-19 infection compared individuals without COVID-19…
  • 2023 International Congress

    Impact of dopamine replacement therapy on shame in Parkinson’s disease patients

    S. Catalano Chiuvé, D. Benis, A. Zulet, P. Krack, V. Fleury (Geneva, Switzerland)

    Objective: This study aims to investigate the effect of dopaminergic replacement therapy (DRT) on shame using emotional dynamic rating scales during ON and OFF-DRT states.…
  • 2023 International Congress

    Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson’s disease.The AMBITIOUS Study Protocol

    F. Colucci, M. Avenali, R. de Micco, A. Bacila, S. Cerri, G. Cuconato, V. Franco, D. Franciotta, C. Ghezzi, M. Gastaldi, C. Galandra, G. Germani, P. Mitrotti, G. Ongari, I. Palmieri, M. Picascia, A. Pichiecchio, F. Esposito, M. Cirillo, F. Di Nardo, S. Aloisio, M. Siciliano, M. Fusar Poli, M. Stanziano, B. Garavaglia, F. Cazzaniga, C. Reale, I. Tramacere, S. Priori, P. Amami, S. Piacentini, MG. Bruzzone, M. Grisoli, F. Moda, R. Eleopra, A. Tessitore, EM. Valente, R. Cilia (Milan, Italy)

    Objective: To determine in Parkinson’s disease (PD) patients carrying GBA mutation the role of Ambroxol (ABX) on the progression of cognitive performance (primary aim), motor…
  • 2023 International Congress

    Feasibility and acceptability of implementing dignity therapy as a supportive intervention for people with movement disorders.

    D. Labuschagne, J. Fleisher, K. Woo, G. Fitchett (Chicago, USA)

    Objective: To determine the feasibility and acceptability of implementing Dignity Therapy (DT) in a neuropalliative clinic, and to determine preliminary efficacy. Background: Awareness of the…
  • 2023 International Congress

    Clinical and radiological characteristics of elder patients of Parkinson’s disease with the onset age of more than 80 years old

    M. Nomoto, H. Iwaki, R. Nonaka, N. Yano (Imabari, Ehime, Japan)

    Objective: We investigated clinical and radiological findings of elder PD patients with the onset of more than 80 years old using clinical examinations, brain CT/MRI…
  • 2023 International Congress

    Clinical implication of small vessel disease burden on deep brain stimulation outcome in Parkinson’s disease

    J. Lee, S. Jo, S. Lee, MS. Kim, SJ. Chung (Seoul, Republic of Korea)

    Objective: We aimed to investigate the correlation between the small vessel disease (SVD) burden and the 1-year outcome after the globus pallidus interna (GPi) deep…
  • 2023 International Congress

    Normative values for the Instrumented Timed Up and Go test in Parkinsonian populations

    L. Palmerini, I. D'Ascanio, A. Giannoni, G. Calandra-Buonaura, G. Giannini, L. Chiari, P. Cortelli, G. Lopane (Bologna, Italy)

    Objective: This study aims to define normative values for the Instrumented Timed Up and Go test using wearable inertial sensors in people affected by Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 193
  • 194
  • 195
  • 196
  • 197
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley